10-K: Viridian Therapeutics Reports Positive Phase 3 Data, Eyes BLA Submission for TED Treatment

Viridian Therapeutics' 10-K filing highlights positive Phase 3 results for veligrotug in thyroid eye disease (TED) and outlines plans for BLA submission, while also advancing its FcRn inhibitor portfolio.

Summary

• Viridian Therapeutics is focused on developing best-in-class medicines for serious and rare diseases.
• The company's lead program, veligrotug, achieved positive topline data in Phase 3 trials (THRIVE and THRIVE-2) for both active and chronic TED.
• A BLA submission for veligrotug is anticipated in the second half of 2025, with an MAA submission to the EMA in the first half of 2026.
• VRDN-003, a subcutaneous formulation of veligrotug, is also in pivotal Phase 3 development, with topline data expected in the first half of 2026 and a BLA submission by the end of 2026.
• The company is advancing its FcRn inhibitor portfolio, including VRDN-006 and VRDN-008, with IND submissions expected by the end of 2025.
• Viridian believes its current cash, cash equivalents, and short-term investments of $717.6 million will be sufficient to fund operations into the second half of 2027.
• The company reported a net loss of $269.9 million for the year ended December 31, 2024.

Sentiment

Score: 7

Explanation: The document presents a balanced view with positive clinical trial results and future plans, but also acknowledges the risks and challenges inherent in drug development and commercialization.

Positives

• Positive Phase 3 data for veligrotug in both active and chronic TED.
• Prolonged half-life demonstrated by VRDN-003, supporting less frequent dosing.
• Advancement of FcRn inhibitor portfolio with promising NHP data.
• Strong cash position providing runway into the second half of 2027.
• Completion of enrollment in STRIVE clinical trial, exceeding enrollment target.

Negatives

• The company has a history of net losses and expects to continue incurring significant losses for the foreseeable future.
• The company is dependent on third parties to manufacture its product candidates.
• The company faces substantial competition in the TED and FcRn inhibitor markets.
• The company is subject to risks related to litigation and other legal proceedings.

Risks

• Clinical trials are inherently risky, and the company may fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities.
• Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable.
• The company's product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval.
• The company relies on third parties to conduct its nonclinical development activities and clinical trials, manufacture its product candidates, and perform other services.
• The company faces substantial competition and its competitors may discover, develop, or commercialize products faster or more successfully than the company.
• The company's future success depends in part on its ability to attract, retain, and motivate qualified personnel.
• The company may be subject to risks related to litigation and other legal proceedings that may materially adversely affect its business, operating results or financial condition.

Future Outlook

The company anticipates submitting a BLA for veligrotug in the second half of 2025 and an MAA to the EMA in the first half of 2026. Topline data for REVEAL-1 and REVEAL-2 is expected in the first half of 2026, with a BLA submission for VRDN-003 anticipated by the end of 2026. The company expects to generate VRDN-006 proof-of-concept IgG reduction data in the third quarter of 2025 and anticipates submitting an IND for VRDN-008 by the end of 2025.

Management Comments

• The company believes that its current cash, cash equivalents and short-term investments will be sufficient to fund its operations, including its clinical development plan described elsewhere in this Annual Report, and enable it to fund its operating expenses and capital expenditure requirements into the second half of 2027.

Industry Context

The TED market is currently dominated by Amgen's Tepezza, but Viridian is positioning itself to be a strong competitor with both its IV and subcutaneous formulations. The FcRn inhibitor market is also competitive, with Argenx's Vyvgart leading the way, but Viridian aims to address limitations of current agents with its engineered molecules.

Comparison to Industry Standards

• Amgen's Tepezza achieved approximately $1.8 billion in net sales in the U.S. in 2024, demonstrating the market potential for TED therapies.
• Argenx's efgartigimod (Vyvgart) generated approximately $2.2 billion in net sales in 2024, highlighting the commercial opportunity for FcRn inhibitors.
• The company's VRDN-008 demonstrated three times the half-life of efgartigimod in NHP studies, suggesting a potentially best-in-class profile.

Related Party Transactions

• The company has a license agreement with Zenas BioPharma, which is considered a related party transaction due to Fairmount Funds Management LLC's ownership stake in both companies.
• The company has an antibody and discovery option agreement with Paragon Therapeutics, Inc., which is considered a related party transaction due to Fairmount Funds Management LLC's ownership stake in both companies.

Stakeholder Impact

• Positive clinical trial results and potential regulatory approvals could benefit patients with TED and other autoimmune diseases.
• Successful commercialization of product candidates could generate revenue and increase shareholder value.
• The company's growth and development activities could create employment opportunities.

Next Steps

• Submit a BLA for veligrotug in the second half of 2025.
• Submit an MAA to the EMA for veligrotug in the first half of 2026.
• Report topline data for REVEAL-1 and REVEAL-2 in the first half of 2026.
• Submit a BLA for VRDN-003 by the end of 2026.
• Generate VRDN-006 proof-of-concept IgG reduction data in the third quarter of 2025.
• Submit an IND for VRDN-008 by the end of 2025.
• Initiate an auto-injector study in 2025 to enable launching VRDN-003 in an auto-injector device, if approved.

Key Dates